- Home
- FSI vs OTLK Comparison
FSI vs OTLK Comparison
Compare FSI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSI
- OTLK
- Stock Information
- Founded
- FSI 1991
- OTLK 2010
- Country
- FSI Canada
- OTLK United States
- Employees
- FSI N/A
- OTLK N/A
- Industry
- FSI Recreational Games/Products/Toys
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSI Consumer Discretionary
- OTLK Health Care
- Exchange
- FSI Nasdaq
- OTLK Nasdaq
- Market Cap
- FSI 46.5M
- OTLK 48.3M
- IPO Year
- FSI 1999
- OTLK 2016
- Fundamental
- Price
- FSI $4.15
- OTLK $1.72
- Analyst Decision
- FSI
- OTLK Strong Buy
- Analyst Count
- FSI 0
- OTLK 5
- Target Price
- FSI N/A
- OTLK $10.20
- AVG Volume (30 Days)
- FSI 24.9K
- OTLK 390.5K
- Earning Date
- FSI 05-23-2025
- OTLK 05-23-2025
- Dividend Yield
- FSI 2.31%
- OTLK N/A
- EPS Growth
- FSI 9.09
- OTLK N/A
- EPS
- FSI 0.24
- OTLK N/A
- Revenue
- FSI $38,234,860.00
- OTLK N/A
- Revenue This Year
- FSI $21.91
- OTLK N/A
- Revenue Next Year
- FSI $42.35
- OTLK $288.46
- P/E Ratio
- FSI $18.04
- OTLK N/A
- Revenue Growth
- FSI N/A
- OTLK N/A
- 52 Week Low
- FSI $1.65
- OTLK $0.87
- 52 Week High
- FSI $7.24
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- FSI 56.53
- OTLK 59.21
- Support Level
- FSI $4.12
- OTLK $1.35
- Resistance Level
- FSI $5.09
- OTLK $2.04
- Average True Range (ATR)
- FSI 0.25
- OTLK 0.13
- MACD
- FSI 0.12
- OTLK 0.03
- Stochastic Oscillator
- FSI 50.65
- OTLK 56.92
About FSI Flexible Solutions International Inc. (CDA)
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.